Sino Biopharmaceutical (HK:1177) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Sino Biopharmaceutical has entered into a global collaboration with Biosion and Aclaris Therapeutics to develop an anti-TSLP monoclonal antibody, BSI-045B. Aclaris will pay over $40 million in cash and 19.9% in common stock to Sino Biopharmaceutical, alongside potential regulatory and sales milestone payments exceeding $900 million. This strategic partnership aims to advance treatments for conditions such as asthma and atopic dermatitis.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
